John Smestad, MD, PhD
Assistant Professor
Locations
- Froedtert Hospital
- Clinical Cancer Center - Froedtert Hospital
Specialties
- Medical Oncology
Languages
- English
Clinical Cancer Center - Froedtert Hospital
Education
- MD - Doctor of Medicine
- PhD
Research Areas of Interest
- Clinical Trial
- Extracellular Matrix
- Immunotherapy
- Melanoma
- Oncolytic Virotherapy
- Oncolytic Viruses
- Sarcoma
- Tumor Microenvironment
Research Experience
- Acylation
- Energy Metabolism
- Epigenomics
- Melanoma
- Protein Processing, Post-Translational
- Sarcoma
- Transcriptome
Clinical Expertise
- Melanoma
- Sarcoma
Publications
-
A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.
(Zakharia Y, Kim D, Freesmeier M, Frees M, Mott S, Monga V, Laux D, Javed A, Rieth J, Smestad J, Milhem M.) Cancer. 2026 Feb 15;132(4):e70326 PMID: 41701511 PMCID: PMC12912253 02/17/2026
-
(Smestad J, Rieth J, Laux D, Milhem M.) Cells. 2025 Oct 17;14(20) PMID: 41148835 PMCID: PMC12563648 10/28/2025
-
(Varun Monga, John Rieth, Benjamin Miller, Hisakazu Hoshi, Carlos Chan, Bryan Allen, Carryn Anderson, Kristen Plichta, Munir Tanas, Jonathan Davick, Steven Varga, Laura Stephens, Sarah L. Mott, John Smestad, Gustavo Fernandes Godoy Almeida, Mohammed Milhem.) JCO Oncology Advances. Phase Ib/II Trial of Pharmacologic Ascorbate With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcoma of the Trunk and Extremities Varun Monga, John Rieth, Benjamin Miller, Hisakazu Hoshi, Carlos Chan, Bryan Allen, Carryn Anderson, Kristen Plichta, Munir Tanas, Jonathan Davick, Steven Varga, Laura Stephens, Sarah L. Mott, John Smestad, Gustavo Fernandes Godoy Almeida, Mohammed Milhem JCO Oncology Advances 2025 :2 12/11/2025
-
An in Vitro Selection Strategy Identifying Naked DNA That Localizes to Cell Nuclei.
(Smestad J, Wilbanks B, Maher LJ 3rd.) J Am Chem Soc. 2019 Nov 20;141(46):18375-18379 PMID: 31702902 PMCID: PMC7047663 11/09/2019
-
Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations.
(Smestad JA, Maher LJ 3rd.) BMC Cancer. 2019 Jun 24;19(1):619 PMID: 31234811 PMCID: PMC6591808 06/27/2019
-
(Wilbanks B, Smestad J, Heider RM, Warrington AE, Rodriguez M, Maher LJ 3rd.) Nucleic Acid Ther. 2019 Jun;29(3):126-135 PMID: 30855209 PMCID: PMC6555174 03/12/2019
-
(Heider RM, Smestad JA, Lemus HN, Wilbanks B, Warrington AE, Peters JP, Rodriguez M, Maher LJ 3rd.) Mol Ther Methods Clin Dev. 2018 Jun 15;9:270-277 PMID: 29707601 PMCID: PMC5918178 05/01/2018
-
(Perwein MK, Smestad JA, Warrington AE, Heider RM, Kaczor MW, Maher LJ 3rd, Wootla B, Kunbaz A, Rodriguez M.) Expert Opin Biol Ther. 2018 May;18(5):545-560 PMID: 29460650 02/21/2018
-
(Smestad J, Erber L, Chen Y, Maher LJ 3rd.) iScience. 2018 Apr 27;2:63-75 PMID: 29888767 PMCID: PMC5993049 06/12/2018
-
(Smestad J, Hamidi O, Wang L, Holte MN, Khazal FA, Erber L, Chen Y, Maher LJ 3rd.) Oncotarget. 2018 Jan 19;9(5):6109-6127 PMID: 29464059 PMCID: PMC5814199 02/22/2018
-
(Hamidi O, Young WF Jr, Gruber L, Smestad J, Yan Q, Ponce OJ, Prokop L, Murad MH, Bancos I.) Clin Endocrinol (Oxf). 2017 Nov;87(5):440-450 PMID: 28746746 PMCID: PMC5854189 07/27/2017
-
(Hayashi Y, Toyomasu Y, Saravanaperumal SA, Bardsley MR, Smestad JA, Lorincz A, Eisenman ST, Cipriani G, Nelson Holte MH, Al Khazal FJ, Syed SA, Gajdos GB, Choi KM, Stoltz GJ, Miller KE, Kendrick ML, Rubin BP, Gibbons SJ, Bharucha AE, Linden DR, Maher LJ 3rd, Farrugia G, Ordog T.) Gastroenterology. 2017 Aug;153(2):521-535.e20 PMID: 28438610 PMCID: PMC5526732 04/26/2017